Oncimmune Holdings plc (ONC ), has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases using its proprietary NavigAIDTM autoimmune disease characterisation panel.
Oncimmune will explore the autoantibody profiles of patients with four key autoimmune diseases:
- Systemic lupus erythematosus
- Sjögren's syndrome
- Rheumatoid arthritis
- Sicca syndrome
The initial phase of this project, including the reporting of profiled data, is scheduled to be completed by the end of calendar year 2021 and with revenue recognition therefore in the current FY22 financial year to May 2022.
Dr Adam M Hill, CEO of Oncimmune, said: "We are delighted that this global pharmaceutical company has again chosen to partner with Oncimmune, for our world class autoantibody biomarker profiling technology and autoimmune expertise. We are confident that this latest programme will form part of a larger and long-term collaboration and we look forward to supporting their programmes in immunology further through clinical development.
"This new contract is also a good illustration of the growing uptake of our services, validating our decision to invest in the physical and human infrastructure of our platform to increase capacity significantly, with further pipeline conversion expected over the coming months and beyond."
View from VOX
This is Oncimmune’s second agreement with this global Pharma thereby demonstrating both the quality of the autoantibody biomarker profiling technology and the broader value proposition for pharmaceutical and biotechnology companies in their clinical development programmes.
The programme is Oncimmune's second agreement with this global partner, and further validates the value of Oncimmune's technology in supporting
Shares in ONCI Have traded within the 160p to 195p range over the past three months whilst maintaining more than 20% appreciation over a 12 month time period.
Reasons to ONC
Oncimmune Holdings’ focus is to harness the immune system’s sophisticated response to disease to detect cancer earlier and to support the development of better therapies.
Leading Proprietary Technology Portfolio
The company believes the key to improving cancer survival is early detection and optimal selection for therapy. Oncimmune's immuno-diagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.
Oncimmune’s core technology also powers its ImmunoINSIGHTS service; a proprietary platform that enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.
The group’s EarlyCDT Lung blood test was previously featured on an ITV news broadcast last weekend titled ‘New Blood Test Provides Breakthrough in Lung Cancer Detection Rates’.
The feature highlighted that, in the UK, more than 35,000 people die of lung cancer each year and most have their lung cancer diagnosed late thereby lowering their chances of survival. 80% of lung cancer cases are diagnosed in the latest stages of the disease.
The EarlyCDT test works to identify the immune system's response to the presence of lung cancer. The test detects antibodies present in the body, enabling clinicians to focus their diagnosis on identifying the disease and treating it earlier than current clinical practice.
It has previously been shown that Oncimmune’s EarlyCDT Lung blood test can detect lung cancer on average four years before standard of care and has shown in a large National Health Service (NHS) trial that it can reduce late stage lung cancer presentation by 36%.
Inflection Point to Commercialisation
The Company now believes it has made the point of inflection as it matures from an R&D business into a commercial entity evidenced through its deepening commercial relationships with Industry Partners such as Roche
Fully Funded
The Company is now fully funded to develop all its commercial activities and drive revenues.
Follow News & Updates from Oncimmune Holdings plc here: